EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Breaking down barriers to improve phage therapy delivery

Tiffany Luong, Izabela Rybicka, Patrick Blankenberg, Krystyna Dąbrowska, Paul L Bollyky

Cell Host & Microbe · 2026-07 · 34 (7) · 1285-1301

DOI: 10.1016/j.chom.2026.06.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cell Host & Microbe, 2026-07. Verfasst von Tiffany Luong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA. Hauptthemen laut MEDLINE: Phage Therapy, Bacteriophages, Bacterial Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: NIAID NIH HHS, NIBIB NIH HHS, National Institute of Allergy and Infectious Diseases Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is growing interest in the development of bacteriophages as therapies for antimicrobial-resistant infections, but effective delivery of phages remains a barrier. This review examines the opportunities and challenges involved in the development of phages as drugs, focusing on phage delivery. We first review current practices and success rates for clinical phage therapy and recent advances in phage selection and design. Next, we frame ongoing delivery challenges in the context of what is known about phage biology and phage pharmacokinetics. We then explore barriers to effective phage delivery alongside dosing and administration strategies used to overcome them, followed by an examination of recent innovations in phage formulations and biomaterials technologies. Finally, we highlight outstanding questions and challenges in the field. We conclude that optimizing delivery is a key determinant of the success of phage therapy and that the integration of microbiology, materials science, and pharmacology will enable more consistent success.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyBacteriophagesBacterial InfectionsHumansAnimalsBacteria

Stichwörter der Autor:innen

antimicrobial resistancebacteriabacteriophage therapydeliveryphagepharmacology

Autor:innen und Institutionen

  • Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
  • Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
  • Laboratory of Phage Molecular Biology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland; Faculty of Medicine, Wroclaw University of Science and Technology, 5…
  • Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, CA 94305, USA. Electronic address: pbollyky@stanford.edu.

Förderung

  • NIAID NIH HHS
  • NIBIB NIH HHS
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research

Zitieren

APA

Luong, T., Rybicka, I., Blankenberg, P., Dąbrowska, K., & Bollyky, P. L. (2026). Breaking down barriers to improve phage therapy delivery. Cell Host & Microbe, 34(7), 1285-1301. https://doi.org/10.1016/j.chom.2026.06.013

Vancouver

Luong T, Rybicka I, Blankenberg P, Dąbrowska K, Bollyky PL. Breaking down barriers to improve phage therapy delivery. Cell Host & Microbe. 2026;34(7):1285-1301. doi:10.1016/j.chom.2026.06.013

BibTeX
@article{Luong2026,
  author = {Luong, Tiffany and Rybicka, Izabela and Blankenberg, Patrick and Dąbrowska, Krystyna and Bollyky, Paul L},
  title = {Breaking down barriers to improve phage therapy delivery},
  journal = {Cell Host & Microbe},
  year = {2026},
  volume = {34},
  number = {7},
  pages = {1285--1301},
  doi = {10.1016/j.chom.2026.06.013}
}
Kostenlos starten →